liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intralymphatic allergen immunotherapy against pollen allergy. A 3-year open follow-up study of 10 patients
Linköping University, Department of Clinical and Experimental Medicine, Division of Neuro and Inflammation Science. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Allergy Center.ORCID iD: 0000-0003-1745-6816
Linköping University, Department of Clinical and Experimental Medicine, Division of Neuro and Inflammation Science. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Allergy Center.
Futurum, Academy of Health and Care, Jönköping, Sweden.
Show others and affiliations
2018 (English)In: Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, E-ISSN 1534-4436, Vol. 121, no 5, p. 626-627Article in journal (Refereed) Published
Abstract [en]

To date, allergen immunotherapy (AIT) is the only treatment that affects the long-term development of allergic rhinoconjunctivitis and induces clinical tolerance primarily by stimulating regulatory T (Treg) cells, attenuating T helper 2 (Th2) responses and synthesis of blocking antibodies1. Conventional AIT with subcutaneous injections, sublingual tablets or drops is effective, but consumes time and resources 2.

Place, publisher, year, edition, pages
Elsevier, 2018. Vol. 121, no 5, p. 626-627
Keywords [en]
Immunotherapy, Intralymphatic, Allergy, Rhinoconjunctivitis, T-cells
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-150594DOI: 10.1016/j.anai.2018.07.010ISI: 000448665400022PubMedID: 30021119OAI: oai:DiVA.org:liu-150594DiVA, id: diva2:1242675
Note

Funding agencies: Region Ostergotland; Allergy Center in Linkoping; Medical Research Council of Southeast Sweden (FORSS); Bergh Foundation; Asthma and Allergy Association of Sweden

Available from: 2018-08-28 Created: 2018-08-28 Last updated: 2019-04-09Bibliographically approved

Open Access in DiVA

fulltext(751 kB)1 downloads
File information
File name FULLTEXT01.pdfFile size 751 kBChecksum SHA-512
f8481abe683e1712ce176cd232d28a746f265d8ca6b0af9c4cb175c2d26144ebf01b972349b3b58b44d0216f752e89db22dc9909ee3c6f28b81f521bc795e362
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Ahlbeck, LarsNyström Kronander, UllaJenmalm, Maria

Search in DiVA

By author/editor
Ahlbeck, LarsAhlberg, EmelieNyström Kronander, UllaBjörkander, JanneJenmalm, Maria
By organisation
Division of Neuro and Inflammation ScienceFaculty of Medicine and Health SciencesAllergy CenterDepartment of Clinical and Experimental Medicine
In the same journal
Annals of Allergy, Asthma & Immunology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 1 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 342 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf